688336 三生国健
已收盘 11-20 15:00:00
资讯
新帖
简况
股市必读:三生国健新发布《三生国健:第五届董事会第二十一次会议决议公告》
证券之星 · 03:09
股市必读:三生国健新发布《三生国健:第五届董事会第二十一次会议决议公告》
三生国健(688336)披露以集中竞价交易方式回购股份的预案,11月19日股价上涨0.11%
证券之星 · 11-19 17:47
三生国健(688336)披露以集中竞价交易方式回购股份的预案,11月19日股价上涨0.11%
三生国健(688336.SH)拟2000万元至4000万元回购股份
智通财经 · 11-18 19:34
三生国健(688336.SH)拟2000万元至4000万元回购股份
11月16日三生国健跌8.51%,富国精准医疗混合A基金重仓该股
证券之星 · 11-16
11月16日三生国健跌8.51%,富国精准医疗混合A基金重仓该股
11月13日三生国健跌5.67%,富国精准医疗混合A基金重仓该股
证券之星 · 11-13
11月13日三生国健跌5.67%,富国精准医疗混合A基金重仓该股
三生国健(688336)11月11日主力资金净卖出1433.39万元
证券之星 · 11-12
三生国健(688336)11月11日主力资金净卖出1433.39万元
三生国健最新公告:实控人提议回购2000万至4000万元股份
证券之星 · 11-11
三生国健最新公告:实控人提议回购2000万至4000万元股份
自免新时代,三生国健稳步走好创新之路
格隆汇 · 11-06
自免新时代,三生国健稳步走好创新之路
股市必读:三生国健新发布《三生国健:关于仲裁事项的进展公告》
证券之星 · 11-06
股市必读:三生国健新发布《三生国健:关于仲裁事项的进展公告》
三生国健(688336)披露关于仲裁事项的进展公告,11月4日股价上涨6.4%
证券之星 · 11-04
三生国健(688336)披露关于仲裁事项的进展公告,11月4日股价上涨6.4%
11月4日三生国健涨6.40%,富国精准医疗混合A基金重仓该股
证券之星 · 11-04
11月4日三生国健涨6.40%,富国精准医疗混合A基金重仓该股
三生国健涨6.40%,中邮证券二个月前给出“买入”评级
证券之星 · 11-04
三生国健涨6.40%,中邮证券二个月前给出“买入”评级
三生国健目标价涨幅超70%,108股获券商推荐
同花顺 · 10-28
三生国健目标价涨幅超70%,108股获券商推荐
股市必读:三生国健三季报 - 第三季度单季净利润同比增长3.65%
证券之星 · 10-26
股市必读:三生国健三季报 - 第三季度单季净利润同比增长3.65%
国金证券:给予三生国健买入评级
证券之星 · 10-23
国金证券:给予三生国健买入评级
三生国健前三季度净利润增长47.29% 自免管线价值逐步兑现
东方财富网 · 10-23
三生国健前三季度净利润增长47.29% 自免管线价值逐步兑现
三生国健(688336)披露2026年第三季度报告,10月22日股价下跌5.47%
证券之星 · 10-22
三生国健(688336)披露2026年第三季度报告,10月22日股价下跌5.47%
三生国健最新公告:前三季度净利润同比增长47.29%
证券之星 · 10-22
三生国健最新公告:前三季度净利润同比增长47.29%
10月22日三生国健跌5.47%,平安医疗健康混合A基金重仓该股
证券之星 · 10-22
10月22日三生国健跌5.47%,平安医疗健康混合A基金重仓该股
三生国健(688336)10月21日主力资金净卖出2070.07万元
证券之星 · 10-22
三生国健(688336)10月21日主力资金净卖出2070.07万元
加载更多
公司概况
公司名称:
三生国健药业(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2020-07-22
主营业务:
三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普(重组人II型肿瘤坏死因子受体-抗体融合蛋白)。
发行价格:
28.18
{"stockData":{"symbol":"688336","market":"SH","secType":"STK","nameCN":"三生国健","latestPrice":26.53,"timestamp":1795158000000,"preClose":28.28,"halted":0,"volume":5650606,"delay":0,"changeRate":-0.0619,"floatShares":896000000,"shares":896000000,"eps":3.4455,"marketStatus":"已收盘","change":-1.75,"latestTime":"11-20 15:00:00","open":27.78,"high":28,"low":26.5,"amount":152000000,"amplitude":0.053,"askPrice":26.54,"askSize":1,"bidPrice":26.53,"bidSize":59,"shortable":0,"etf":0,"ttmEps":3.4455,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":5,"adr":0,"adjPreClose":28.28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1795138200000,1795145400000],[1795150800000,1795158000000]],"highLimit":31.11,"lowLimit":25.45,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":896225429,"isCdr":false,"pbRate":2.74,"roa":"--","peRate":7.699898,"roe":"6.84%","epsLYR":4.7,"committee":0.341121,"marketValue":23777000000,"turnoverRate":0.0063,"status":1,"afterMarket":{"amount":53060,"volume":2000,"close":26.53,"buyVolume":0,"sellVolume":1372,"time":1795160037746,"indexStatus":"已收盘 11-20 15:30:00","preClose":28.28},"floatMarketCap":23777000000},"requestUrl":"/m/hq/s/688336","defaultTab":"news","newsList":[{"id":"2684901672","title":"股市必读:三生国健新发布《三生国健:第五届董事会第二十一次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2684901672","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684901672?lang=zh_cn&edition=full","pubTime":"2026-11-20 03:09","pubTimestamp":1795115351,"startTime":"0","endTime":"0","summary":"公司公告汇总三生国健:第五届董事会第二十一次会议决议公告三生国健药业(上海)股份有限公司于2026年11月18日召开第五届董事会第二十一次会议,审议通过《关于以集中竞价交易方式回购公司股份方案的议案》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026112000001444.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684922448","title":"三生国健(688336)披露以集中竞价交易方式回购股份的预案,11月19日股价上涨0.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2684922448","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684922448?lang=zh_cn&edition=full","pubTime":"2026-11-19 17:47","pubTimestamp":1795081653,"startTime":"0","endTime":"0","summary":"截至2026年11月19日收盘,三生国健报收于28.28元,较前一交易日上涨0.11%,最新总市值为253.45亿元。公司于2026年11月19日披露《关于以集中竞价交易方式回购股份的预案》。公告显示,三生国健药业(上海)股份有限公司拟以自有资金通过集中竞价交易方式回购公司股份,回购金额不低于2,000万元且不超过4,000万元,回购价格不超过50元/股。回购期限为董事会审议通过之日起12个月内。相关股东在未来3至6个月内暂无减持计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111900031945.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684989189","title":"三生国健(688336.SH)拟2000万元至4000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2684989189","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684989189?lang=zh_cn&edition=full","pubTime":"2026-11-18 19:34","pubTimestamp":1795001678,"startTime":"0","endTime":"0","summary":"智通财经APP讯,三生国健(688336.SH)发布公告,公司拟2000万元至4000万元回购股份,回购价格不超过50元/股,回购股份将在未来适宜时机用于员工持股计划或股权激励。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1525235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683869483","title":"11月16日三生国健跌8.51%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683869483","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683869483?lang=zh_cn&edition=full","pubTime":"2026-11-16 16:50","pubTimestamp":1794819000,"startTime":"0","endTime":"0","summary":"证券之星消息,11月16日三生国健跌8.51%创60日新低,收盘报29.35元,换手率0.93%,成交量8.37万手,成交额2.47亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为30.0亿元,最新净值2.8967,较上一交易日下跌1.9%,近一年下跌15.04%。富国精准医疗混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111600022583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683573192","title":"11月13日三生国健跌5.67%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683573192","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683573192?lang=zh_cn&edition=full","pubTime":"2026-11-13 16:45","pubTimestamp":1794559558,"startTime":"0","endTime":"0","summary":"证券之星消息,11月13日三生国健跌5.67%,收盘报32.08元,换手率0.67%,成交量6.04万手,成交额1.99亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为30.0亿元,最新净值2.9528,较上一交易日上涨0.13%,近一年下跌11.27%。富国精准医疗混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111300030050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682662536","title":"三生国健(688336)11月11日主力资金净卖出1433.39万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2682662536","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682662536?lang=zh_cn&edition=full","pubTime":"2026-11-12 08:32","pubTimestamp":1794443527,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年11月11日收盘,三生国健报收于32.79元,下跌1.35%,换手率0.47%,成交量4.22万手,成交额1.38亿元。近5日资金流向一览见下表:三生国健融资融券信息显示,融资方面,当日融资买入1317.36万元,融资偿还1287.73万元,融资净买入29.63万元。三生国健主营业务:从事抗体药物的研发、生产及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111200006599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682303882","title":"三生国健最新公告:实控人提议回购2000万至4000万元股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2682303882","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682303882?lang=zh_cn&edition=full","pubTime":"2026-11-11 18:19","pubTimestamp":1794392376,"startTime":"0","endTime":"0","summary":"三生国健(688336.SH)公告称,公司实际控制人、董事长LOUJING提议公司以集中竞价交易方式回购部分A股股份,回购资金总额不低于2000万元且不超过4000万元,回购股份将用于股权激励或员工持股计划。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026111100037106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681887140","title":"自免新时代,三生国健稳步走好创新之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2681887140","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681887140?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:38","pubTimestamp":1793929105,"startTime":"0","endTime":"0","summary":"从“中国首款”到“全球认可”,三生国健的故事,正是中国创新药从跟跑、并跑到局部领跑的时代缩影。","market":"hk","thumbnail":"https://img2.gelonghui.com/b9ad4-da7a3911-98bb-4d51-9817-ae7af4cf2bb8.jpg?guru_height=852&guru_width=1280&guru_size=143965","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/b9ad4-da7a3911-98bb-4d51-9817-ae7af4cf2bb8.jpg?guru_height=852&guru_width=1280&guru_size=143965"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/7314469","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681392003","title":"股市必读:三生国健新发布《三生国健:关于仲裁事项的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2681392003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681392003?lang=zh_cn&edition=full","pubTime":"2026-11-06 01:10","pubTimestamp":1793898629,"startTime":"0","endTime":"0","summary":"截至2026年11月5日收盘,三生国健报收于34.17元,上涨3.86%,换手率0.77%,成交量6.92万手,成交额2.35亿元。公司公告汇总:公司收到仲裁申请人奥海生物变更仲裁请求,索赔总额约5.07亿元,案件已开庭但尚未裁决;控股股东富健药业承诺全额承担公司可能承担的付款义务。公司控股股东富健药业承诺全额承担公司依据仲裁裁决、调解书或和解协议所需承担的付款义务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600001676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680008057","title":"三生国健(688336)披露关于仲裁事项的进展公告,11月4日股价上涨6.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680008057","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680008057?lang=zh_cn&edition=full","pubTime":"2026-11-04 22:20","pubTimestamp":1793802039,"startTime":"0","endTime":"0","summary":"截至2026年11月4日收盘,三生国健报收于32.9元,较前一交易日上涨6.4%,最新总市值为294.86亿元。近日,三生国健药业(上海)股份有限公司发布《关于仲裁事项的进展公告》。公告显示,公司收到上海国际经济贸易仲裁委员会送达的变更仲裁请求申请书,申请人奥海生物技术(上海)有限公司要求公司赔偿因终止履行《合作协议》造成的损失、评估费、律师费、担保费、仲裁费用等共计约507,026,026.62元。案件已开庭审理,尚未作出裁决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400043747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680036486","title":"11月4日三生国健涨6.40%,富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680036486","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680036486?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:16","pubTimestamp":1793783782,"startTime":"0","endTime":"0","summary":"证券之星消息,11月4日三生国健涨6.40%,收盘报32.9元,换手率1.03%,成交量9.26万手,成交额2.98亿元。根据2026基金Q3季报公募基金重仓股数据,重仓该股的公募基金共7家,其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为30.0亿元,最新净值2.8021,较上一交易日下跌1.69%,近一年下跌17.01%。富国精准医疗混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032276.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680171036","title":"三生国健涨6.40%,中邮证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2680171036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680171036?lang=zh_cn&edition=full","pubTime":"2026-11-04 17:16","pubTimestamp":1793783762,"startTime":"0","endTime":"0","summary":"今日三生国健涨6.40%,收盘报32.9元。2026年9月4日,中邮证券研究员盛丽华,徐智敏发布了对三生国健的研报《授权收入驱动业绩高增,创新管线迈入密集兑现期》,该研报对三生国健给出“买入”评级。此外,国金证券研究员甘坛焕,唐玉青,开源证券研究员余汝意,聂媛媛近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400032270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678433826","title":"三生国健目标价涨幅超70%,108股获券商推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2678433826","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678433826?lang=zh_cn&edition=full","pubTime":"2026-10-28 09:17","pubTimestamp":1793150220,"startTime":"0","endTime":"0","summary":"南财投研数据显示,10月27日,券商给予上市公司目标价共84次,按最新收盘价计算,目标价涨幅排名居前的公司有三生国舰虹软科技、富临精工,目标价涨幅分别为71.93%、68.59%、67.89%,分别属 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20261028/c681168250.shtml","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20261028/c681168250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678353136","title":"股市必读:三生国健三季报 - 第三季度单季净利润同比增长3.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678353136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678353136?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:54","pubTimestamp":1792950853,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘,三生国健报收于33.76元,上涨3.88%,换手率0.67%,成交量6.02万手,成交额1.96亿元。第三季度单季度主营收入5.27亿元,同比上升11.14%;归母净利润2.16亿元,同比上升3.65%;扣非净利润1.83亿元,同比下降6.38%;负债率4.43%,毛利率81.19%,投资收益4949.23万元,财务费用4533.48万元。公司公告汇总三生国健:2026年第三季度报告2026年第三季度营业收入52,677.72万元,同比增长11.14%;年初至报告期末营业收入139,248.04万元,同比增长24.77%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000556.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677289926","title":"国金证券:给予三生国健买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2677289926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677289926?lang=zh_cn&edition=full","pubTime":"2026-10-23 19:00","pubTimestamp":1792753212,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,唐玉青近期对三生国健进行研究并发布了研究报告《授权收入持续驱动业绩高增,在研管线密集推进》,给予三生国健买入评级。 风险提示 研发及商业化不及预期风险、大股东持股集中及关联交易风险最新盈利预测明细如下:该股最近90天内共有8家机构给出评级,买入评级5家,增持评级3家;过去90天内机构目标均价为55.82。本文数据来源于国金证券股份有限公司,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300037398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677192634","title":"三生国健前三季度净利润增长47.29% 自免管线价值逐步兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2677192634","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677192634?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:06","pubTimestamp":1792749960,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯(记者常华科)10月22日晚间,三生国健披露2026年三季报。公告显示,公司前三季度营业收入13.92亿元,同比增长24.77%;归母净利润5.87亿元,同比增长47.29%;扣非归母净利润4.42亿元,同比增长25.55%。与此同时,公司持续加码创新研发投入,前三季度研发费用同比增长35.68%。“公司将保持每年至少一款新品或新适应症申报或上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://stock.eastmoney.com/news/11134,202610233906407687.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.eastmoney.com/news/11134,202610233906407687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677937961","title":"三生国健(688336)披露2026年第三季度报告,10月22日股价下跌5.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677937961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677937961?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:20","pubTimestamp":1792678827,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘,三生国健报收于32.5元,较前一交易日下跌5.47%,最新总市值为291.27亿元。该股当日开盘34.35元,最高34.49元,最低32.26元,成交额达1.76亿元,换手率为0.59%。近日,三生国健药业(上海)股份有限公司披露《2026年第三季度报告》。报告显示,本报告期营业收入52,677.72万元,同比增长11.14%;年初至报告期末营业收入139,248.04万元,同比增长24.77%。利润总额年初至报告期末为62,186.85万元,同比增长50.39%;归属于上市公司股东的净利润为58,746.39万元,同比增长47.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200042770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677959653","title":"三生国健最新公告:前三季度净利润同比增长47.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677959653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677959653?lang=zh_cn&edition=full","pubTime":"2026-10-22 18:02","pubTimestamp":1792663379,"startTime":"0","endTime":"0","summary":"三生国健(688336.SH)公告称,第三季度营业收入为5.27亿元,同比增长11.14%;归属于上市公司股东的净利润为2.16亿元,同比增长3.65%。前三季度营业收入为13.92亿元,同比增长24.77%;归属于上市公司股东的净利润为5.87亿元,同比增长47.29%。注:公司Q3净利润2.16亿,Q2净利润1.93亿,据此计算,Q3净利润环比增长11%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200031416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677348958","title":"10月22日三生国健跌5.47%,平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2677348958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677348958?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:37","pubTimestamp":1792658276,"startTime":"0","endTime":"0","summary":"证券之星消息,10月22日三生国健跌5.47%创60日新低,收盘报32.5元,换手率0.59%,成交量5.3万手,成交额1.76亿元。根据2026基金半年报公募基金重仓股数据,重仓该股的公募基金共33家,其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。平安医疗健康混合A目前规模为17.61亿元,最新净值2.1586,较上一交易日上涨0.4%,近一年下跌15.97%。平安医疗健康混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200028545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159760","BK0239","688336"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677898988","title":"三生国健(688336)10月21日主力资金净卖出2070.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677898988","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677898988?lang=zh_cn&edition=full","pubTime":"2026-10-22 08:34","pubTimestamp":1792629285,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月21日收盘,三生国健报收于34.38元,下跌2.05%,换手率0.45%,成交量4.0万手,成交额1.4亿元。近5日资金流向一览见下表:三生国健融资融券信息显示,融资方面,当日融资买入1565.96万元,融资偿还2071.11万元,融资净偿还505.15万元。三生国健主营业务:从事抗体药物的研发、生产及销售业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200007099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688336","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1795163234904,"stockEarnings":[{"period":"1week","weight":-0.1685},{"period":"1month","weight":-0.1933},{"period":"3month","weight":-0.4058},{"period":"6month","weight":-0.3303},{"period":"1year","weight":-0.3739},{"period":"ytd","weight":-0.3052}],"compareEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0422},{"period":"3month","weight":-0.0839},{"period":"6month","weight":-0.1301},{"period":"1year","weight":-0.0935},{"period":"ytd","weight":-0.0986}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三生国健药业(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"21636人(较上一季度增加5.09%)","perCapita":"41422股","listingDate":"2020-07-22","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路399号","registeredCapital":"89622万元","survey":" 三生国健药业(上海)股份有限公司的主营业务是抗体药物的研发、生产和销售。公司的主要产品是益赛普(重组人II型肿瘤坏死因子受体-抗体融合蛋白)。","listedPrice":28.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三生国健,688336,三生国健股票,三生国健股票老虎,三生国健股票老虎国际,三生国健行情,三生国健股票行情,三生国健股价,三生国健股市,三生国健股票价格,三生国健股票交易,三生国健股票购买,三生国健股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三生国健(688336)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三生国健(688336)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}